Saturday 17 October 2026
Export CURX’s income statement to Excel — free account
Curanex Pharmaceuticals Inc
CURX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 4,671.4% and free cash flow fell 272.3%, each against the same quarter a year earlier.
4.62
0.21
−4.35%
Follow CURX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 6.44 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 183.60 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | — | — | — | 0 | (4) | |||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | — | 0 | (4) | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | — | (0.60) | (3.40) | |||||
| Cash flow | — | — | — | — | — | — | — | — | (0.84) | (8.22) | |||||
| Capex | — | — | — | — | — | — | — | — | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (0.84) | (8.22) | |||||
| Book value | — | — | — | — | — | — | — | — | 0.76 | 8.80 | |||||
| Shares, m | — | — | — | — | — | — | — | — | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (1) | (10) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | (1) | (10) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 1 | 11 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | — | 0 | (5) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | 1 | 11 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (69.85) | ||||
| ROIC | — | — | — | — | — | — | — | — | (64.37) | (42.42) | |||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (72.09) | |||||
Negative figures in brackets.
Charts ten years each
Curanex Pharmaceuticals Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR | $8.1M | — (loss-making) | — | — | n/m | −510.28% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KPTI Karyopharm Therapeutics Inc. | $8.0M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| CNSP CNS Pharmaceuticals, Inc. | $7.9M | — (loss-making) | — | — | n/m | +33.70% (above 0%: growing) | 0.00% | 0.00% | Compare |
| APRE Aprea Therapeutics, Inc. | $7.8M | — (loss-making) | — (loss-making) | −98.40% (below 0%: shrinking) | n/m | −5.22% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SNGX Soligenix Inc. | $7.7M | — (loss-making) | — (loss-making) | −98.89% (below 0%: shrinking) | n/m | +37.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CURX Curanex Pharmaceuticals Inc | $7.6M | — (loss-making) | — | — | n/m | −272.32% (below 0%: shrinking) | — | 0.00% | |
| MBRX Moleculin Biotech, Inc. | $7.6M | 0.0× | — | — | n/m | −19.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CALC CalciMedica Inc. | $7.4M | — (loss-making) | — | — | n/m | +31.42% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XCUR Exicure, Inc. | $7.3M | — (loss-making) | — (loss-making) | −80.51% (below 0%: shrinking) | n/m | +65.38% (above 0%: growing) | 100.00% | 0.00% | Compare |
| Median of peers | $7.8M | — | — | −89.45% | — | +13.10% | 0.00% | 0.00% |
Curanex Pharmaceuticals Inc (CURX) key facts
- Curanex Pharmaceuticals Inc (CURX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CURX traded at $4.62, a market capitalization of $7.6 million.
- Return on equity was −72.1% and debt-to-equity 0.00.
Curanex Pharmaceuticals Inc (CURX) Latest News
No news at this impact. Lower the threshold for more.